Management Quality -- 4.5/10

Unprecedented negative guidance: For the first time in company history, Novo Nordisk guided for declining adjusted sales (-5% to -13% CER) and declining adjusted operating profit (-5% to -13% CER) in 2026. This follows a year where initial guidance of 16-24% growth was lowered twice and still missed. The guidance reflects structural pricing pressure from the MFN deal ($245/mo Medicare pricing), the $199 self-pay channel, and competitive share loss to Eli Lilly.

30 consecutive years of dividend increases. Novo Nordisk raised its dividend to DKK 11.70 per share in 2025, extending the longest dividend growth streak in European pharma. CFO Karsten Munk Knudsen remains in place and has provided continuity through the leadership transition. These are the only two positive signals in an otherwise deeply concerning management picture.

4.5/10. This is the lowest-scoring dimension for NVO and the primary driver of the -0.4 composite adjustment (from 6.3 to 5.9). CEO Lars Fruergaard Jorgensen departed after ~8 years, replaced by Mike Doustdar who has less than one year in the role. The Head of US Operations has turned over twice in 12 months. Head of Product/Portfolio also replaced. Only 3 of 8 verifiable guidance promises were met -- a 37.5% hit rate driven by systematic over-promising on growth (16-24% guided, 6.4% delivered for 2025), CagriSema weight loss (25% guided, 22.7% delivered), and FCF (DKK 57-65B guided, DKK -14.7B actual in 2024). The company has issued its first-ever negative revenue guidance for 2026. The only positives are CFO stability and the 30-year dividend streak. 6 of 8 red flags are triggered. This is a turnaround management story -- the new team must establish credibility through 2-3 quarters of execution before this score can improve.